Nov 10 (Reuters) - AstraZeneca PLC:
* ASTRAZENECA PLC - TEZEPELUMAB PHASE III TRIAL MET PRIMARY ENDPOINT
* ASTRAZENECA - TRIAL ALSO MET PRIMARY ENDPOINT IN PATIENTS WITH LOW LEVELS OF EOSINOPHILS
* ASTRAZENECA - POSITIVE RESULTS FROM NAVIGATOR PHASE III TRIAL FOR POTENTIAL NEW MEDICINE TEZEPELUMAB IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.